The status of KRAS mutations in patients with non-small cell lung cancers from mainland China

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 1013-1020

  Li, Mei ^a   Liu, Lina ^a   Liu, Zhimin ^a   Yue, Shichang ^a   Zhou, Luming ^b   Zhang, Qiuping ^a   Cheng, Shihua ^a   Li, Rachel W ^c,d   Smith, Paul N ^d   Lu, Shen ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c The Australian National University   (Australia)

^d CANBERRA HOSPITAL   (Australia)

Author keywords

High resolution melting; KRAS; Mutation; Non small cell lung cancer

Indexed keywords

K RAS PROTEIN;

ADULT; AGED; ARTICLE; ASIAN; CHINA; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE SEQUENCE; GENETIC SCREENING; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMOKING; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR CELLS, CULTURED;

EID: 70449412341     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000529     Document Type: Article

References (38)

1. Parkin M, Tyczynski JE, Boffetta P, Samet J, Shields P and Caporaso N: Lung cancer epidemiology and etiology. In: Pathology and Genetics, Tumours of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC (eds.) World Health Organization Classification of Tumours. IARC Press, Lyon, pp12-15, 2004.
2. Adjei AA: Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062-1074, 2001.
3. Yokota J and Kohno T: Molecular footprints of human lung cancer progression. Cancer Sci 95: 197-204, 2004.
4. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours (review). Int J Oncol 7: 413-421, 1995.
5. Shigematsu H and Gazdar AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262, 2006.
6. Shibata T, Hanada S, Kokubu A, et al: Blackwell publishing Asia gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Sci 98: 985-991, 2007.
7. Paez JG, Jaånne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
8. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
9. Takano T, Ohe Y, Tsuta K, et al: Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with gefitinib. Clin Cancer Res 13: 5385-5390, 2007.
10. Krypuy M, Newnham GM, Thomas DM, Conron M and Dobrovic A: High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 6: 295, 2006.
11. Do H, Krypuy M, Mitchell PL, Fox SB and Dobrovic A: High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8: 142, 2008.
12. Massarelli E, Varella-Garcia M, Tang X, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 13: 2890-2896, 2007.
13. Soung YH, Lee JW, Kim SY, et al: Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 446: 483-488, 2005.
14. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.
15. Siegfried JM, Gillespie AT, Mera R, Casey TJ, Keohavong P, Testa JR and Hunt JD: Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev 6: 841-847, 1997.
16. Keohavong P, DeMichele MAA, Melacrinos AC, Landreneau RJ, Weyant RJ and Siegfried JM: Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 2: 411-418, 1996.
17. Rosell R, Monzó M, Pifarré A, et al: Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res 2: 1083-1086, 1996.
18. Rodenhuis S and Slebos RJC: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52: S2665-S2669, 1992.
19. Sakuma Y, Matsukuma S, Yoshihara M, et al: Distinctive evaluation of non-mucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas. Am J Clin Pathol 128: 100-108, 2007.
20. Baea NC, Chaeb MH, Leec MH, et al: EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 173: 107-113, 2007.
21. Wu C, Hsu H, Liu H, et al: Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 113: 3199-3208, 2008.
22. Tam IY, Chung LP, Suen WS, et al: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12: 1647-1653, 2006.
23. Gautschi O, Huegli B, Ziegler A, et al: Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 254: 265-273, 2007.
24. Hunt JD, Strimas A, Martin JE, et al: Differences in KRAS mutation spectrum in lung cancer cases between African-Americans and Caucasians after occupational or environmental exposure to known carcinogens. Cancer Epidemiol Biomarkers Prev 11: 1405-1412, 2002.
25. Zhou L, Wang L, Palais R, Pryor R and Wittwer CT: High-resolution DNA melting analysis for simultaneous mutation scanning and genotyping in solution. Clin Chem 51: 1770-1777, 2005.
26. Nomoto K, Tsuta K, Takano T, et al: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126: 608-615, 2006.
27. Leeneer KD, Coene I, Popper B, Paepe AD and Claes K: Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: comparison of two high-resolution melting platforms. Clin Chem 54: 982-989, 2008.
28. Koeffler HP, McCormick F and Denny C: Molecular mechanisms of cancer. West J Med 155: 505-514, 1991.
29. Der CJ, Krontiris TG and Cooper GM: Transforming genes of human, bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 79: 3637-3640, 1982.
30. Wong CE, Karnezis AN, Rosario RD, Lauro RD and Balmain A: Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet 40: 1240-1244, 2008.
31. Hsieh RK, Lim KH, Kuo HT, Tzen CY and Huang MJ: Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 128: 317-321, 2005.
32. Zhang G, Lin J, Wang Z, et al: Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol 19: 499-506, 2007.
33. Mu X, Li L, Zhang X, et al: Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res 11: 4289-4294, 2005.
34. Wang Z, Wu YL, Zhang GC, Zhou Q, Xu CR and Guo AL: EGFR/KRAS mutations and gefitinib therapy in chinese NSCLC patients. Onkologie 31: 174-178, 2008.
35. Calvez FL, Mukeria A, Hunt JD, et al: TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 65: 5076-5083, 2005.
36. Riely GJ, Kris MG, Rosenbaum D, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731-5734, 2008.
37. Reed GH and Wittwer CT: Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 50: 1748-1754, 2004.
38. Liew M, Pryor R, Palais R, Meadows C, Erali M, Lyon E and Wittwer C: Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem 50: 1156-1164, 2004.